1,196 Shares in ResMed Inc. $RMD Acquired by Wealth Alliance LLC

Wealth Alliance LLC acquired a new stake in ResMed Inc. (NYSE:RMD) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,196 shares of the medical equipment provider’s stock, valued at approximately $309,000.

A number of other institutional investors have also recently bought and sold shares of RMD. ICW Investment Advisors LLC raised its holdings in ResMed by 0.4% during the 1st quarter. ICW Investment Advisors LLC now owns 11,394 shares of the medical equipment provider’s stock worth $2,551,000 after buying an additional 41 shares during the period. Johnson Investment Counsel Inc. boosted its holdings in shares of ResMed by 2.8% in the second quarter. Johnson Investment Counsel Inc. now owns 1,665 shares of the medical equipment provider’s stock valued at $430,000 after buying an additional 45 shares during the period. Smartleaf Asset Management LLC increased its position in shares of ResMed by 3.9% during the first quarter. Smartleaf Asset Management LLC now owns 1,222 shares of the medical equipment provider’s stock worth $269,000 after acquiring an additional 46 shares in the last quarter. E Fund Management Co. Ltd. raised its holdings in shares of ResMed by 2.8% during the first quarter. E Fund Management Co. Ltd. now owns 1,719 shares of the medical equipment provider’s stock worth $385,000 after acquiring an additional 47 shares during the period. Finally, V Square Quantitative Management LLC lifted its position in ResMed by 3.0% in the 2nd quarter. V Square Quantitative Management LLC now owns 1,747 shares of the medical equipment provider’s stock valued at $451,000 after acquiring an additional 51 shares in the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Stock Down 0.4%

NYSE:RMD opened at $251.91 on Friday. ResMed Inc. has a twelve month low of $199.92 and a twelve month high of $293.81. The firm has a market capitalization of $36.76 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 1.75 and a beta of 0.87. The company has a quick ratio of 2.53, a current ratio of 3.44 and a debt-to-equity ratio of 0.11. The stock’s 50 day moving average price is $266.91 and its two-hundred day moving average price is $262.73.

ResMed (NYSE:RMD) last released its quarterly earnings data on Friday, October 31st. The medical equipment provider reported $2.55 EPS for the quarter, beating the consensus estimate of $2.49 by $0.06. The company had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.33 billion. ResMed had a return on equity of 25.62% and a net margin of 27.22%.The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.20 EPS. Equities research analysts expect that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Thursday, November 13th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Thursday, November 13th. ResMed’s dividend payout ratio (DPR) is 24.56%.

Analyst Ratings Changes

Several analysts have issued reports on RMD shares. Stifel Nicolaus lifted their price target on ResMed from $240.00 to $270.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Mizuho dropped their target price on ResMed from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. UBS Group raised ResMed to a “strong-buy” rating in a research report on Tuesday, September 16th. Wells Fargo & Company started coverage on shares of ResMed in a research note on Monday, October 13th. They set an “equal weight” rating and a $280.00 price target for the company. Finally, KeyCorp boosted their price objective on shares of ResMed from $298.00 to $299.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $297.45.

Insider Activity at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $252.05, for a total value of $504,100.00. Following the sale, the director directly owned 66,110 shares of the company’s stock, valued at approximately $16,663,025.50. This represents a 2.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Michael J. Rider sold 100 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $274.36, for a total transaction of $27,436.00. Following the completion of the sale, the general counsel owned 11,327 shares of the company’s stock, valued at $3,107,675.72. This trade represents a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 21,182 shares of company stock worth $5,658,783 over the last ninety days. Company insiders own 0.65% of the company’s stock.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.